Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Lipid Absorption
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Hyperglycemia
Atherosclerosis III: Management
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Jul 7, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
Lauren S Yeager1, Ralph G Zinner1, Zhonglin Hao1
1Division of Medical Oncology, University of Kentucky Markey Cancer Center, Lexington, USA.
Pembrolizumab can cause asymptomatic hypertriglyceridemia, a rare immune-related adverse event. Routine monitoring is crucial for patients receiving pembrolizumab (an immune checkpoint inhibitor) to detect and manage such side effects early.
Area of Science:
Background: